Mikrobiomik
Olaia Aurtenetxe is an experienced professional in clinical research with a focus on oncology and childhood cancer. Currently serving as Responsable de Investigacion Clinica at Mikrobiomik since February 2023, Olaia has previously held significant roles including Coordinador de ensayos clinicos oncologia medica and Investigador at Osakidetza from October 2008 to February 2023, where responsibilities included research and project management in pediatric cancer. Olaia began a career at TISA as Azafata and also contributed as an Investigador at Neiker-Tecnalia. Educational qualifications include a Doctorado in Biología from Universidad del País Vasco/Euskal Herriko Unibertsitatea, a Master en Ensayos Clinicos from Universidad de Sevilla, and a Master en oncologia basica y clinica from Universidad del País Vasco/Euskal Herriko Unibertsitatea, alongside a Licenciatura en ciencias from the same institution.
This person is not in any teams
Mikrobiomik
Mikrobiomik is a bio-pharmaceutical company founded to conduct research into and develop medicines based on the human microbiome. Our vision We aspire to be the first company in the world to market a medicine based on faecal microbiota in the EU. To that end, we are holding talks with both the EMA (European Medicines Agency) and the AEMPS (Spanish Agency for Medicines and Health Products) with a view to establishing protocols on the regulatory requirements for securing an MAA (Marketing Authorization Application) via centralised procedure. Our values Mikrobiomik seeks to lead the paradigm shift entailed by designing therapeutic solutions based on the human microbiome through excellence in its processes, empathising with chronic patients for whom no curative treatments are available, always from the perspective of networking with all stakeholders in the sector.